PMID- 12559804
OWN - NLM
STAT- MEDLINE
DCOM- 20031031
LR  - 20191210
IS  - 0264-410X (Print)
IS  - 0264-410X (Linking)
VI  - 21
IP  - 11-12
DP  - 2003 Mar 7
TI  - Co-immunization with plasmids coding the full length and a soluble form of 
      glycoprotein D of HSV-2 induces protective cellular and humoral immune response 
      in mice.
PG  - 1239-45
AB  - At present, the significance of antibody for protection of the female genital 
      tract against infection with HSV-2 remains controversial. In the present study, 
      the ability of a DNA vaccine encoding different forms of glycoprotein D (gD) of 
      herpes simplex virus-2 (HSV-2) to induce simultaneously cellular and humoral 
      responses was evaluated. Mice immunized with a plasmid encoding full length gD 
      (pgD) developed a strong cellular immune response but weak antibody titers in 
      serum and vaginal washings. On the other hand, mice immunized with a plasmid 
      encoding soluble form of gD (pdeltagD) showed high titers of antibodies but a 
      very weak cell-mediated immune response. When mice were immunized simultaneously 
      with both plasmids, cellular and humoral immune responses were elicited. This 
      mice showed neutralizing antibodies in serum and vaginal washings as well as a 
      high number of IFN-gamma secreting cells in spleen. When challenged with 50 
      lethal doses of virus, mice immunized with pgD along with pdeltagD showed a more 
      complete protection than mice immunized with pgD alone. Collectively these 
      results suggest that neutralizing antibodies help cell-mediated immune response 
      for the protection against HSV-2 infection.
CI  - Copyright 2002 Elsevier Science Ltd.
FAU - Flo, Juan
AU  - Flo J
AD  - Laboratorio de Inmunoquimica, Departamento de Quimica Biologica, Facultad de 
      Ciencias Exactas y Naturales, Universidad de Buenos Aires, Pabellon 2 Piso 4to 
      Ciudad Universitaria, Buenos Aires 1428, Argentina. jflo@qb.fcen.uba.ar
LA  - eng
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Vaccine
JT  - Vaccine
JID - 8406899
RN  - 0 (Antibodies, Viral)
RN  - 0 (Antigens, Viral)
RN  - 0 (Vaccines, DNA)
RN  - 0 (Viral Envelope Proteins)
RN  - 0 (Viral Vaccines)
RN  - 0 (glycoprotein D-herpes simplex virus type 2)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Animals
MH  - Antibodies, Viral/*biosynthesis/immunology
MH  - Antigens, Viral/genetics/*immunology
MH  - B-Lymphocytes/immunology
MH  - Estrous Cycle
MH  - Female
MH  - Genetic Vectors/genetics/*immunology
MH  - Herpesvirus 2, Human/genetics/*immunology
MH  - Hypersensitivity, Delayed/immunology
MH  - Immunity, Cellular
MH  - Immunity, Mucosal
MH  - Immunization, Secondary
MH  - Interferon-gamma/metabolism
MH  - Lymphocyte Activation
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mucous Membrane/immunology
MH  - Neutralization Tests
MH  - Sequence Deletion
MH  - Spleen/immunology
MH  - T-Lymphocyte Subsets/immunology/metabolism
MH  - Vaccination
MH  - Vaccines, DNA/*immunology
MH  - Vagina/immunology
MH  - Viral Envelope Proteins/genetics/*immunology
MH  - Viral Vaccines/*immunology
EDAT- 2003/02/01 04:00
MHDA- 2003/11/01 05:00
CRDT- 2003/02/01 04:00
PHST- 2003/02/01 04:00 [pubmed]
PHST- 2003/11/01 05:00 [medline]
PHST- 2003/02/01 04:00 [entrez]
AID - S0264410X02004760 [pii]
AID - 10.1016/s0264-410x(02)00476-0 [doi]
PST - ppublish
SO  - Vaccine. 2003 Mar 7;21(11-12):1239-45. doi: 10.1016/s0264-410x(02)00476-0.